Funding for this research was provided by:
Cancer Research UK (CRUK/07/040)
Received: 9 October 2018
Accepted: 16 January 2019
First Online: 4 February 2019
Ethics approval and consent to participate
: SCALOP-2 has been ethically approved by the National Research Ethics Service Committee South Central – Oxford B (REC reference: 15/SC/0103) and by the MHRA to be conducted in the UK; both parties approve amendments to the study protocol. All participants will provide written informed consent to the site investigator before registration.
: Not applicable
: Celgene Limited are providing an educational grant and free nab-paclitaxel to support the study. Nelfinavir is being provided free of charge to the participating centres. SM is part-funded by Oxford Biomedical Research Centre. MH is MRC-funded.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.